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Today, lentiviral vectors are favorable vectors for RNA interference delivery in anti-HIV therapeutic 
approaches. Nevertheless, problems such as the speciﬁc recognition of target cells and uncontrolled ex­
pression of the transgene can restrict their use in vivo. Herein we present a new HIV-inducible promoter 
to express anti-HIV short hairpin RNA (shRNA) by RNA Pol II in mammalian cells. We likewise showed a 
novel third-generation lentiviral vector system with more safety and a speciﬁc tropism to the target cells. 
The new promoter, CkRhsp, was constructed from the chicken b-actin core promoter with the R region of 
HIV-1 long terminal repeat fused upstream of minimal hsp70 promoter. This system was induced by HIV­
1 Tat, and activates transcription of two shRNAs against two conserved regions of HIV-1 transcripts 
produced in two steps of the virus life cycle. We also mimicked HIV-1 cell tropism by using the HIV-1 
envelope in structure of third-generation lentiviral vector. The new fusion promoter efﬁciently expressed 
shRNA in a Tat-inducible manner. HIV-1 replication was inhibited in transient transfection and stable 
transduction assays. The new viral vector infected only CD4 + cells. CkRhsp promoter may be safer than 
other inducible promoters for shRNA-mediated gene therapies against HIV. The use of the wild envelope 
in the vector packaging system may provide the speciﬁc targeting T lymphocytes and hematopoietic stem 
cells for anti-HIV-1 therapeutic approaches in vivo. 
INTRODUCTION 
Controlling the human immunodeﬁciency virus 
(HIV) infection is a major challenge in both devel­
oped and underdeveloped countries. Although the 
drugs used in antiretroviral therapies have notice­
ably decreased the index of progression to the ac­
quired immune deﬁciency syndrome (AIDS) in HIV-
infected individuals, they are not without major side 
effects and signiﬁcant problems. Pharmacokinetic 
differences between patients result in many drug-
related toxicities. Drug failures for those on anti­
retroviral therapies occur as a result of viral resis­
tance and other problems arising from a lasting 
regimen of chemotherapy.1–3 Therefore, there is a 
necessity to develop alternative therapies for the 
treatment of HIV-infected patients. These genetic-
based therapies include oligonucleotide-based ma­
terials like small interfering RNA (siRNA), suicide 
genes, or transdominant negative proteins. Many of 
these approaches have demonstrated promising re­
sults in limiting viral replication. Some of these ge­
netic therapies have also progressed to clinical trial. 
However, a main limitation in designing anti-HIV 
therapeutic approaches is the ability of the virus 
to escape and become resistant to therapies. As a 
result, it is essential to develop strategies that can 
remarkably restrict the ability of the HIV to become 
resistant to therapy. One way it can be achieved by a 
combination of gene targeting different viral prod­
ucts or early/late steps in the viral life cycle or the 
RNA interference (RNAi) against a conserved region 
in virus transcripts. It can greatly reduce the prob­
ability of virus mutants’ escape.4,5 
Posttranscriptional silencing strategies by RNAi 
are being used by many studies for the develop­
ment of new strategies in antiviral therapies.6,7 
RNAi mainly involves the introduction of siRNA, a 
short, double-stranded RNA molecule with 21–23 
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nucleotides and 3¢ overhang of two nucleotides, 
modiﬁed by the endoribonuclease Dicer. Dicer pro­
motes the activation of the RNA-induced silencing 
complex that is essential for RNAi.8,9 The siRNA 
molecules can be transfected as synthetic double-
stranded RNA or can be achieved by expression 
plasmids as separate sense and antisense strands. 
Another approach is the use of a short hairpin RNA 
(shRNA) 21–29 nucleotides long that can be pro­
cessed to an siRNA molecule.10–12 
Replication-defective lentiviral vectors derived 
from HIV-1 have proven to be very potent to trans-
duce both nonreplicating and replicating cells and 
long-term expression of the therapeutic transgene. 
These properties suggest the advantages of using 
these vectors for gene therapy. Today, lentiviral 
vectors are favorable vectors for RNAi delivery in 
anti-HIV therapeutic approaches.13,14 However, 
problems such as the speciﬁc recognition target cells 
and uncontrolled expression of the transgene can 
restrict their use in vivo. 
To design selective inducible vectors, the HIV 
long terminal repeat (LTR) has been used as the 
promoter by several studies, to control transcrip­
tion of antiviral RNAs and proteins in HIV-infected 
cells.15–19 The LTR promoter is strongly induced by 
Tat, a protein produced in early steps of HIV-1 life 
cycle. Tat binds to the transactivation response 
element (TAR), a stem–loop sequence at the 5¢ LTR 
of viral RNA.20 Two known chimeric promoters on 
this approach are the LTR-hsp18,19 and the CK­
TAR.21,22 The LTR-hsp was constructed from the 
full HIV-1 LTR and Drosophila minimal heat shock 
promoter 70 (DHSP), and was used to Tat-inducible 
expression of anti-HIV shRNA and protein. In this 
promoter, transcription from the DHSP element 
was controlled by the Tat protein attached to TAR 
in LTR and creates a precise transcriptional 
start site downstream of the LTR. This property 
could eliminate non-base-paired sequence in 5¢ of 
shRNA.18 The CK-TAR promoter was created when 
Han and colleagues21 found that LTR sequences 
other than TAR domain are not required for Tat 
transactivation. This promoter is composed of the 
core promoter of the chicken b-actin gene, for the 
binding of transcription factors, fused upstream of 
the viral TAR sequence. In comparison with LTR­
hsp, the CK-TAR promoter could be safer with re­
gard to vector mobilization and insertional muta­
genesis that can occur with the virus LTR. However, 
the CK-TAR promoter cannot make a favorable 
transcriptional start site in shRNA expression ap­
proaches. It also had a relative basal activity in the 
absence of Tat, which reduces its competence in 
selective expression.22 Hence, both promoters may 
not be safe or efﬁcient enough in therapeutic ap­
proaches. 
Given the above explanation, we decided to de­
sign a novel lentiviral delivery system to express 
anti-HIV shRNA against two conserved regions in the 
HIV-1 transcripts. To increase safety and neutralize 
vector mobilization, and also to obtain a favorable 
transcriptional start site in shRNA expression, we 
devised a Tat-inducible promoter in which chicken 
b-actin core promoter with the R region of HIV-1 
LTR was fused upstream of minimal hsp70 pro­
moter and it was named CkRhsp. We also mim­
icked HIV-1 cell tropism by using HIV-1 envelope 
in the structure of lentiviral vectors and investi­
gated its anti-HIV activity in vitro. 
MATERIALS AND METHODS 
ShRNA design 
In this study, two shRNAs were designed to 
target two highly conserved sites in the HIV-1 RNA 
sequence as previously reported.23 These shRNAs 
included 28-nucleotide stem and a 9-base loop11 
(Fig. 1A). The ﬁrst shRNA (T/R) targets Tat/Rev 
transcripts (early products in HIV-1 life cycle) in 
position 5547–5568 of the viral genome. The second 
shRNA (I/V) targets integrase/Vif transcripts (late 
products) in position 4622–4643 of the viral ge­
nome (Fig. 1B). 
Vector constructions 
The CkRhsp-shRNA cassettes were synthesized 
by using sequences of the 278 bp chicken b-actin 
core promoter (pbetaAct plasmid, ATCC, 37507), 
the 99 bp R region of HIV-1 LTR (pLenti6.2/GW 
Figure 1. shRNA information. (A) The shRNA sequence with minimal 
polyadenylation. (B) The HIV-1 genome showing the positions of the two 
target sites. I/V and T/R shRNAs target the overlapping regions in integrase/ 
Vif and Tat/Rev transcripts, respectively. shRNA, short hairpin RNA. 
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plasmid; Invitrogen, Carlsbad, CA), the 294 bp 
minimal hsp70 promoter (pIND plasmid; Invitro­
gen), shRNA sequences, and minimal polyadenyla­
tion (mpolyA), respectively (Fig. 2A). The mpolyA 
sequence was obtained from Xia et al.’s study.12 The 
LTR-I/V cassette was synthesized by using the se­
quence of HIV-1 LTR (pNL4-3, NIH AIDS Research 
and Reference Reagent Program) fused to I/V 
shRNA, upstream of mpolyA. 
The expression vector backbone was a self-
inactivating lentiviral vector, pLenti6.2/GW (In­
vitrogen). Construction and characteristics of the 
pLenti6.2 vector have been previously described.24 
The pLenti/CkRhsp-shRNA vectors were constructed 
by insertion of promoter-shRNA cassettes into cut 
sites of ClaI and  MluI restriction enzymes (Fermen­
tas, Sankt Leon-Rot, Germany). The pLenti/LTR­
shRNA vector is also constructed by insertion of the 
LTR-shRNA cassette into cut sites of ClaI and  MluI 
restriction enzymes. All of the described expression 
cassettes are cloned in reverse orientation (Fig. 2B). 
The pLP-Env plasmid is constructed by PCR 
ampliﬁcation of the full-length envelope gene of HIV 
type 1 from HIV-1 provirus plasmid (pNL4-3), using 
the forward primer AAACACGTGAGAATGAGAG 
TGAAGGAGAAATATC and reverse primer AAA 
CCGCGGAATTTATAGCAAAATCCTTTCCA (cut 
sites are underlined). The PCR amplicons were then 
replaced with gag/pol genes in the pLP1 plasmid 
(Invitrogen) by PmlI and  SacII restriction enzymes 
(Fermentas) and ligation. 
Transfection assay 
HEK293 cells (ATCC, CRL1573) were cultured 
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) 
with 10% fetal bovine serum (FBS). Twenty-four 
hours before transfection, the cells were trypsi­
nized and counted, and 5 · 104 cells were plated in 
the 48-well format at 80% conﬂuency with 200 ll 
DMEM and 10% FBS without antibiotics. The next 
day, cells were cotransfected with 100 ng of pNL4-3 
plasmid and 50 ng of shRNA vectors in 0.7 ll lipo­
fectamine according to the manufacturer’s protocol 
(Invitrogen). Six hours after transfection, the me­
dium was replaced with 200 ll medium with anti­
biotics. Culture supernatants were collected at 24, 
48, and 72 hr posttransfection and analyzed for p24 
antigen by the enzyme-linked immunosorbent as­
say (ELISA) kit (Clontech, Seoul, South Korea) and 
using an ELISA plate reader (BioTek, Winooski, 
VT) according to the manufacturer’s instructions. 
ShRNA expression assay 
Total RNA was extracted from 107 cells acquired 
from 24 hr transfection plates by the mirPremier 
microRNA Isolation Kit (Sigma, Munich, Germany). 
The ﬁrst-strand cDNA was synthesized using stem– 
loop primers and reverse transcription enzyme 
Figure 2. Construct of the Tat-inducible promoter and the lentiviral packaging system. (A) Two schematic representations of the CkRhsp-shRNA expression 
cassette. The chicken b-actin core promoter along with the TAR loop region was fused upstream of the minimal hsp70 promoter. The basal transcription is blocked by 
the negative transcription elongation factor (NTEF). The hsp70 promoter can be relieved by a heterodimer of cyclin T1-Cdk 9 called the positive transcription elongation 
factor b (PTEFb). The recent complex is recruited to the promoter by the HIV Tat protein and can phosphorylateNTEF, which leads to the dissociation of NTEF from the C-
terminal of RNA polymerase II and releasing the elongation block. AS, antisense strand; L, loop; S, sense strand; TS, transcription start. (B) Transfer vector backbone is 
the pLenti6.2 lentiviral vector containing a chimeric 5¢ LTR in which the U3 sequence is replaced with the Rous sarcoma virus (RSV) promoter, the packaging signal (C), 
the HIV-1 Rev response element (RRE) sequence, the antibiotic resistance gene of blasticidin (BSD) driven by murine phosphoglycerate kinase-1 (PGK) promoter, and 
the 3¢ LTR without the cis regulatory sequences in the U3 region. CkRhsp-shRNAs and LTR-shRNA cassettes were inserted directly upstream of the PGK promoter of 
BSD in pLenti6.2 vector in the reverse orientation. (C) The helper plasmid pLP1 contains the gag and pol genes and RRE sequence under the control of the CMV 
promoter, pLP2 contains the HIV Rev gene driven by the RSV promoter, and pLP-Env contains the envelope gene sequence of HIV-1 type 1 driven by the CMV promoter. 
PolyA indicates the polyadenylation signal from the human b-globin gene. Color images available online at www.liebertpub.com/hum 
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(Invitrogen) according to manufacturer’s proto­
col. The cDNAs were then quantiﬁed in triplicate, 
using forward and reverse primers and Maxima 
SYBR Green Master Mix (Fermentas) in Bio-Rad 
iQ5 Real-Time PCR system (Bio-Rad, Munich, 
Germany). The shRNA expression was normal­
ized against U6-snRNA endogenous control as 
previously described.25 The relative expression  
was calculated using the 2 -DCt (DCt = Ct of control 
gene - Ct of target gene). 
Lentiviral vector production 
A third-generation lentiviral vector system was 
used to produce transducing vectors as described 
by Yam et al.26 HEK293T cells (ATCC, CRL-3216) 
were cultured to achieve the 90% conﬂuency in a 
100 mm culture dish. The cells were cotransfected 
with 15 lg of transfer vector with the appropriate 
insert, 15 lg of pLP1(Gag/Pol), 10 lg of pLP2(Rev) 
(Invitrogen), and 5 lg of pLP-Env (Fig. 2C), by the 
calcium phosphate precipitation protocol.27 Eight 
hours posttransfection, the culture medium was 
replaced by the fresh medium. After 24 and 48 hr of 
transfection, the culture supernatants were har­
vested and pooled. Vector supernatant was collected 
from the three harvests and cleared by centrifuga­
tion at 250 g for 6min at 4�C, and then ﬁltered 
through a 0.45 lm ﬁlter  and concentrated by  Lenti-
X Concentrator kit (Clontech). The viral titer was 
determined by p24 level according to the ELISA 
kit’s user guide (Clontech). Lentiviral vector titers 
ranged from 4 · 108 to 6 · 108 infectious units/ml. 
Lentiviral vector transduction 
and HIV-1 challenge 
To transduce the human T-cell line CEM (ATCC, 
CCL-119) and HEK293 cell line (as CD4-negative), 
2 · 105 cells were plated in a 15 ml centrifuge tube 
containing 1 ml RPMI1640 medium. Lentiviral 
vectors were added to the tube in a multiplicity of 
infection (MOI) of 10 without polybrene. Twenty-
four hours posttransduction, the cells were centri­
fuged and cultured in a fresh medium containing 
8 lg/ml of antibiotic blasticidin (Invitrogen) every 3 
days. After 12 days, 106 live cells were infected with 
HIV-1 strain NL4-3 at an MOI of 0.001. The cells 
were then incubated overnight and washed three 
times with Hanks’ balanced salt solution and cul­
tured in the medium with 20% FBS. On days 3–18 
after infection, the cell cultures were changed ev­
ery 3 days, and the supernatant was collected for 
the HIV-1 p24 assay. Cell viability was also deter­
mined by the trypan blue staining. ShRNA ex­
pression was analyzed on all time points in cells 
transduced with the CkRhsp-T/R-I/V vector. 
Statistical analysis 
The differences between variables were identi­
ﬁed by ANOVA test. Data analyses were performed 
by SPSS software version 17 (SPSS Inc., Chicago, 
IL). A p-value less than 0.05 was considered sta­
tistically signiﬁcant. 
RESULTS 
The CkRhsp promoter expressed shRNA 
in a Tat-inducible manner 
In this study, we constructed two types of plas­
mid vectors in which anti-HIV shRNAs are ex­
pressed from two Tat-inducible promoters by RNA 
polymerase II, the CkRhsp (novel promoter), and 
HIV-1 LTR (for comparison) (Fig. 2A). To test 
whether Tat made by HIV-1 could sufﬁciently in­
duce inhibition from the CkRhsp promoter, the 
HEK293 cells are cotransfected with shRNA ex­
pression plasmids and a HIV-1 infectious clone 
(pNL4-3). HIV-1 gene expression was then mea­
sured by p24 assay on cell supernatants. Results in 
Fig. 3A show that the virus gene expression sig­
niﬁcantly decreased when cells were cotransfected 
with both shRNA vectors and pNL4-3 (plasmid 
containing Tat gene) ( p <0.001). In addition, the in­
hibition of virus gene expression by pLenti/CkRhsp 
plasmids was more efﬁcient than that by the pLenti/ 
LTR plasmid ( p = 0.015) (Fig. 3A). 
To investigate efﬁcacy of the new promoter, we 
measured the level of mature siRNAs resulting from 
transfection. As shown  in  Fig.  3B, there  is  a consid­
erable level of shRNA expression when cells were 
cotransfected with shRNA plasmids and pNL4-3, but 
not in cells transfected only with shRNA plasmids. 
Importantly, low expression of shRNAs in the ab­
sence of Tat protein (no pNL4-3) shows a very low 
basal activity of the CkRhsp promoter compared with 
the LTR promoter ( p <0.001). Moreover, shRNA ex­
pression by pLenti/CkRhsp plasmids was little more 
than that by the pLenti/LTR plasmid (Fig. 3B). 
HIV-1 inhibition in transient 
transfection assay 
To test pLenti vectors in a transient expression 
setting and also to investigate its potency against 
HIV-1, the HEK293 cells were cotransfected with 
the shRNA plasmids and pNL4-3. As results in Fig. 
3A show, in day 3 posttransfection, there was an 
approximate 80–97% inhibition of HIV-1 replication 
by pLenti/CkRhsp-shRNA plasmids relative to 
pNL4-3 and irrelevant shRNA ( p <0.001). The level 
of inhibition mediated by pLenti/CkRhsp-T/R-I/V 
was signiﬁcantly higher than that seen with pLenti/ 
CkRhsp-T/R and pLenti/CkRhsp-I/V ( p = 0.23). 
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Figure 3. siRNA expression driven by the RNA Pol II promoter inhibits HIV-1 gene expression. (A) HEK293 cells were cotransfected with proviral pNL4-3 and pLenti 
constructs and the p24 protein level was determined on day 3. HIV-1 gene expression was efﬁciently inhibited by shRNA constructs driven by both CkRhsp and LTR 
promoters. (B) The real-time PCR analysis of siRNAs extracted from HEK293 cells shows high expression in cells cotransfected with transfer vectors and pNL4-3 (as 
Tat producer). siRNA expression levels in no pNL4-3-transfected cells indicate that the basal activity of the LTR promoter is signiﬁcantly higher compared with CkRhsp. 
All the data are from the three independent experiments. siRNA, small interfering RNA. Color images available online at www.liebertpub.com/hum 
HIV-1 inhibition in stable transduction assay 
The CEM cell line was stably transduced with 
vectors containing the CkRhsp-shRNA cassettes and 
wild envelope (Fig. 2B). The transduced cells were 
then challenged with HIV-1 strain NL4-3. At six 
time points, culture supernatants were obtained and 
were analyzed for p24 levels and expressed as a p24 
chart. The percentage of live cells was also deter­
mined by trypan blue staining and demonstrated 
as a cell viability chart. As observed in Fig. 4A, our 
lentiviral vector can potentially infect CEM cells 
without chemical regents such as polybrene. 
Our results in Fig. 4A show that a strong virus 
inhibition was observed in cells transduced with 
Figure 4. HIV-1 challenge assay. (A) CEM cells transduced with pLenti/CkRhsp-shRNA vectors were challenged with the HIV-1 NL4-3 strain. (B) Cells were 
stained with trypan blue and counted using hemocytometer at the indicated days. All the data are from the three independent experiments. Color images 
available online at www.liebertpub.com/hum 
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shRNA vectors relative to NL4-3 strains ( p <0.001). 
At 15–18 days postinfection, cells transduced with 
single-shRNA vectors showed viral replication as an 
increase in p24 level, whereas the dual-shRNA 
vectors decreased virus replication and increased 
cell viability percentage ( p = 0.021) (Fig. 4). 
Lentiviral vectors with wild envelope have 
a speciﬁc tropism to CD41cells 
To investigate efﬁcacy of novel vector in speciﬁc 
tropism to CD4 + cells, we have analyzed shRNA 
expression level in CEM (as CD4 +) and HEK293 
(as CD4 -) cells transduced with CkRhsp-shRNA 
vectors. Our results in Fig. 5 show that shRNA was 
considerably expressed only in CEM cells and no 
expression was detected in HEK293 cells. 
DISCUSSION 
To avoid the side effects of chemotherapy and 
development of drug-resistant HIV-1 strains in the 
treatment of HIV-infected patients, there is a need to 
develop alternative therapeutic approaches such as 
gene therapy.4 The unique features of HIV-1  virus  
and the various mechanisms of pathogenesis in­
volved in disease progression and ultimately death 
pose considerable problems in the design of effective 
gene therapeutic setting. Stable integration, high 
mutability of the viral genome, the tendency of virus 
to latency, and its accumulation in immunologically 
privileged cells such as brain are some of these 
Figure 5. Investigation of vector-speciﬁc tropism to CD4 +cells via siRNA 
expression analysis in transduced cell lines. siRNAs extracted from CEM and 
HEK293 cells were transduced with the CkRhsp-T/R-I/V vector and expression 
levels were determined by real-time PCR. All the data are from the three inde­
pendent experiments. Color images available online at www.liebertpub.com/hum 
features.28 Therefore, it is more appropriate that 
different stages of virus life cycle and multiple 
products be targeted for more effective therapy. 
During the past decade, RNAi gene silencing has 
proven to be an efﬁcient tool for disrupting speciﬁc 
genes’ function and is considered as a potential an­
tiviral agent in gene therapy strategies. Successful 
application of this novel technology in vivo requires 
vector development in the ﬁelds of safety and speciﬁc 
transducing target cells. An advantage of the RNAi­
based therapies compared with protein-based ap­
proaches is lack of immunogenicity of the RNAi 
molecules.29,30 For the effective inhibition of HIV-1 
replication with an RNAi-based gene therapy, the 
use of multiple shRNAs simultaneously and prefer­
ably targeting highly conserved sequences have been 
proposed.31–34 In most previous studies, the targets 
of siRNAs or shRNAs in HIV-1 transcripts are not in 
fact highly conserved, and only a few studies focused 
on targeting conserved HIV-1 sequences.23,35–38 As 
previously reported39,40 and our results at 15–18 
days postinfection show (Fig. 4A), HIV-1 can escape 
from inhibition by mutations in sequences targeted 
by a single shRNA. We therefore decided to design 
two shRNAs for targeting two highly conserved re­
gions in the HIV-1 genome in a dual-shRNA ex­
pression from a novel RNA polymerase II promoter. 
There are potent advantages to utilizing RNA 
polymerase II in shRNA expression, including in­
ducible transcription and tissue-speciﬁc promot­
ers. 12 Several studies have focused on the use of HIV 
LTR for HIV induction of anti-HIV genes’ expres­
sion.41,42 In the present study, we demonstrated an 
HIV-1-inducible shRNA promoter in which the 
chicken b-actin core promoter with the R region of 
HIV-1 LTR was fused upstream of the Drosophila 
minimal hsp70 promoter (Fig. 2A). It is already 
known that the full LTR other than TAR element is 
not necessary for Tat transactivation.21 In addition, 
the use of HIV LTR may increase the risks of vector 
mobilization and insertional mutagenesis, which 
may not be appropriate in vivo approaches. There­
fore, we exchanged the U3 region in HIV LTR with a 
safer alternative promoter such as the chicken b­
actin promoter for transcription of the TAR se­
quence, which may be more favorable for in vivo 
applications. The U5 region of HIV LTR is also re­
moved. The U5 sequence contains sequences such as 
primer binding sites that are involved in reverse 
transcription.43 With regard to this point, adding 
these sequences among the two LTRs in the vector 
genome (triple U5) may interfere with the efﬁcient 
functioning of vectors in the target cells. As previ­
ously reported by Xia et al.,12 the hsp70 promoter 
and HIV-1 LTR show considerable similarities in 
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transcription initiation. Both promoters are ar­
rested by promoter-proximal pausing and are re­
leased by the Tat element (Fig. 2A). Hence, we 
decided to create a Tat-inducible promoter by fusing 
the minimal hsp70 promoter to downstream of the 
chicken b-actin core promoter and TAR element 
(Fig. 2A), in contrast to Unwalla et al.’s study,18 in 
which the hsp70 promoter had been attached to full-
length LTR. In the CkRhsp promoter, transcription 
initiation from the hsp70 promoter is dependent on 
binding Tat to TAR element in its upstream. There­
fore, the shRNA expression occurs only in HIV-1­
infected cells containing the Tat protein. As is un­
derstood from the results of Fig. 3, the new chimeric 
promoter can efﬁciently help to minimize no-Tat 
basal activity and elimination of non-base-paired 
sequences of 5¢ end in shRNA expression. These re­
sults demonstrated that, unlike HIV LTR in the 
CkRhsp promoter, transcription initiating from the 
hsp70 can be more efﬁciently processed into an siR-
NA. Transcripts resulting from the HIV LTR would 
have an additional sequence (TAR and U5) at the 5¢ 
end of the sense strand that would reduce recogni­
tion and processing to mature siRNAs.12,18,19 
Compared with the previous studies that used 
VSVG-pseudotyped vector to cell transduction, a re­
markable change in this work is to deliver anti-HIV 
shRNA constructs via a lentiviral vector with the 
HIV-1 envelope. This modiﬁcation mimicked speciﬁc 
tropism to the target cells without using chemicals 
such as polybrene, which raises the chance of using 
these vectors for in vivo approaches. As siRNA ex­
pression analysis in Fig. 5 shows, only CD4 + cells 
(CEM) were transduced by our new vector. 
In summary, we have provided a novel third-
generation lentiviral vector system to inhibit HIV­
1 replication with speciﬁc features, including more 
safety, HIV-inducible, and speciﬁc targeting, one 
step closer to a treatment of the HIV-infected in­
dividuals. These experiments indicated that RNAi 
can be expressed by a Tat-inducible promoter other 
than the full HIV-1 LTR. The chimeric CKRhsp 
promoter, as well as LTR, can efﬁciently be induced 
by Tat, but with more safety, lower risk of LTR 
mobilization, and favorable start site in shRNA 
expression. RNAi is a potent antiviral agent in a 
gene therapy approach, specially expressing mul­
tiple shRNAs to target high conserved sequences 
from a single viral vector. The use of wild envelope 
in the vector packaging system may provide the 
speciﬁc targeting T lymphocytes and hematopoi­
etic stem cells for anti-HIV-1 therapeutic ap­
proaches in vivo. 
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